Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.🕒 1 min read
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.
Continue Reading
-
PM Narendra Modi Hails Indian Cricketers, Para-Athletes For Making 2025 A “Memorable Year In Sports”
- Fact Check: President Trump Exaggerates, Misstates Facts On Washington Crime
- Ghosts Of 1971 Crisis: Why France Moving Gold From US Is Spooking Markets
- RBL Bank Q1 results: Net profit declines 46% to Rs 200 crore; NII drops 13% to 1481 crore
- ‘I’ll hit it’: Samson reveals Sooryavanshi’s fearless chat with Dravid before IPL debut
-
Lottery Baron’s Son Launches New Party, Will Contest Polls In Puducherry
- Most Popular Korean Actors And Their Earnings
- The Siliguri storm: Richa Ghosh battled a finger fracture to fire India to World Cup glory
-
Who Is Kim Ju Ae, North Korean Leader Kim Jong Un’s Daughter And “Most Likely” Successor
- Arjun Tendulkar Bowls Inch-Perfect Yorkers In Nets, Leaves Everyone Stunned
